Navigation Links
Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0286181/Women's-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

SummaryGlobalData, the industry analysis specialist, has released its new report, "Women's Infertility - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global women's infertility therapeutics market. The report identifies the key trends shaping and driving the global women's infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women's infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global women's infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat fr
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
2. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
3. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
4. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
5. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
6. Reportlinker Adds Advances in Biopharmaceutical Technology in China
7. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
8. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
9. Reportlinker Adds Stem Cells Market And Applications. 2009-2015
10. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
11. Reportlinker Adds Global Nucleic Acid Testing Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Wis . - He shares company secrets. He thinks business ... in small, two-person project teams to improve the flow of ... time to accommodate REM work. , ,There is a method ... some of his insights at the recent Wisconsin Entrepreneurs' Conference ...
... I've been running hard up the Vista/Office 2007 ... plain worn out. Productivity is in the basement. Frustration has ... write a column, synchronize my e-mail, launch a presentation, and ... doing for years. The challenge started when I got a ...
... a manufacturer of gene chips for pharmaceutical research, will discontinue ... its acquisition by Roche , the Basel, Switzerland based ... in the IPO, but under the terms of a definitive ... percent of the privately held NimbleGen from shareholders for $272.5 ...
Cached Biology Technology:Visions: Chicago software exec Jason Fried breaks (almost) all the rules 2Visions: Chicago software exec Jason Fried breaks (almost) all the rules 3Picking Vista sure seemed like a good idea at the time 2Picking Vista sure seemed like a good idea at the time 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 2NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 4
(Date:4/17/2014)... drug under clinical trials to treat tuberculosis could be ... act against various bacteria, fungal infections and parasites, yet ... Illinois chemists and collaborators. , Led by U. of ... different ways the drug SQ109 attacks the tuberculosis bacterium, ... pathogens from yeast to malaria and how targeting ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014The development of stem ... on the ability to characterize stem cell populations based ... Cross have discovered a new marker that is highly ... human umbilical cord blood, which they describe in an ... journal from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... Professor Luca Razzari of the nergie Matriaux Tlcommunications ... from the John R. Evans Leaders Fund of ... acquisition of state-of-the-art biotech and nanophotonics equipment. To ... the Ministre de l,Enseignement suprieur, de la Recherche, ... These new laboratories will help us develop new ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
... commercially prized fish from the depths of the world's ... ability to recover is constrained by the fishes' long ... said today at the annual meeting of the American ... fish species living at depths greater than 500 meters ...
... way to fight leukemia might be to knock out a ... study shows. , The findings suggest that a drug ... be an effective therapy. , But such a ... offer an effective one-two punch against drug-resistant forms of chronic ...
... Uganda who self-paid for their antiretroviral medications experienced interruptions ... supply logistical disruptions. These treatment interruptions led to ... , These findings by a team led by researchers ... and UCSF are reported in the April 22, 2007 ...
Cached Biology News:Long-lived deep-sea fishes imperiled by technology, overfishing 2Long-lived deep-sea fishes imperiled by technology, overfishing 3Knocking out survival protein could aid leukemia treatment 2Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2
... Idaho Technologys R.A.P.I.D. System (Ruggedized Advanced ... real-time, PCR thermocycler designed for field ... environments. In addition to its ruggedness, ... sensitivity and specify as the LightCycler ...
... ES Cell Characterization Kit consists of two ... as well as four ES cell-specific antibodies ... • Stem cells have become the subject ... their therapeutic potential and because they raise ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Note: Evaluated for its amino acid acceptor activity ... acids Ala, Asp, Gly, Ile, Lys, Pro, Thr, ... Preparation Unit Definition: One unit will yield an ... of water (1 cm light path). ...
Biology Products: